Recent Posts

• GeneVentiv targeting gene therapies for hemophilia, Pompe disease
• Gene therapy developed at Duke to be commercialized by a local biotechnology company
• GeneVentiv Announces Global Licensing Agreement for Universal Gene Editing Therapy for Infantile Onset and Late Onset Pompe Disease
• GeneVentiv Welcomes New Scientific Advisory Board Member, Sylvia Fong
• GeneVentiv Therapeutics Awarded $2.5 Million SBIR Grant to Advance Gene Therapy for All Hemophilias, with or without Inhibitors